Background
==========

Chronic obstructive pulmonary disease (COPD) is globally one of the leading causes of morbidity, disability, and mortality according to World Health Organization (<http://www.who.int/respiratory/copd/en/>). For decades, COPD was considered simply as a disease with progressive airflow limitation. Lately it has become obvious that COPD patients suffer simultaneously from several extra-pulmonary diseases such as cardiovascular diseases, diabetes, osteoporosis, musculoskeletal dysfunction, chronic kidney and heart failure, anxiety, depression, and addiction diseases \[[@B1]-[@B5]\]. In several population studies both increased morbidity and mortality are associated with lung function impairment \[[@B6]-[@B13]\]. Furthermore, co-morbidities have additional impact on health, for example the response to treatment received for coronary artery disease is worse in patients with co-existing COPD \[[@B14],[@B15]\]. The underlying causes of multi-morbidity in COPD are still poorly understood. The co-occurrence of the diseases may appear simply due to patients' aging, or due to shared risk factors or etiological pathways. The latter is compatible with the hypothesis that COPD sustains systemic inflammation in the body \[[@B4]\].

Spirometry alone is not enough in clinical practice to predict the future outcome of COPD as for instance exacerbation rates and co-morbidity may contribute as well \[[@B16]\]. This has initiated studies to develop a multidimensional score with a better predictive power to monitor progression of COPD than FEV~1~ alone. Health related quality of life (HRQoL) has become one of the components of interest. So far our experience on HRQoL in COPD has mainly emerged from randomised clinical trials in which HRQoL is frequently evaluated as a secondary end point \[[@B17],[@B18]\]. Contrary to clinical practice, the severity of COPD is often restricted and patients with severe co-occurring diseases are under-represented or even excluded. Traditionally, the number of female patients has been limited in clinical trials as well, while it is known that this affects the prevalence of co-morbidities \[[@B19]\] and treatment decisions \[[@B20]\]. Therefore, determining the effect of co-morbidities and gender on HRQoL has become increasingly important also in real world observational studies. There is also a need for the development of programs that enhance supportive care for patients with severe COPD \[[@B21]\]. This is particularly important since HRQoL may offer a good outcome-measure for holistic interventional studies that take into account patient's physical, psychological, social and spiritual well-being.

In the present study we aim to estimate the contribution of common co-morbidities on self-reported HRQoL among COPD patients by using two questionnaires: the AQ20 focusing on respiratory health \[[@B22]\] and the 15D focusing on generic health \[[@B23]\]. Both questionnaires are simple and short, and can be used easily in clinical practice with high response and completion rates \[[@B24],[@B25]\]. AQ20 has discriminative properties and responsiveness comparable to more complex questionnaires such as SGRQ \[[@B24]\], and 15D and AQ20 have convergent validity to measure HRQoL in COPD \[[@B25]\]. We also studied the association between HRQoL and the 5-year-mortality.

Methods
=======

Subjects
--------

Hospital Discharge Registries were used to identify all patients with COPD who had visited the Pulmonary Clinics of the Helsinki and Turku University Hospitals during the years 1995--2006. The databases were screened by ICD10 code J44.8 and contained all patients between 18 to 75 years of age. The upper level was selected due to our study design, which included a 10-year follow-up. All identified patients were invited to the study without further selection. The recruitment was done through a two-phase mailing campaign, through which altogether 844 patients participated the study \[[@B26]\], after which their diagnosis was carefully assessed going through the medical records by a pulmonologist. This resulted in 739 confirmed COPD patients (clinical symptoms and airway obstruction according GOLD) with smoking related disease. The enrolment occurred during the years 2005--2007. All the participants gave informed consent to collect, merge, and analyse their comprehensive medical history from all the healthcare providers who had treated them during the past 5--10 years. Participants of the Health2000 survey (N = 5000) were used as age and gender matched population controls to avoid biased inferences. Their diagnostic data had been gathered from the hospital discharge registries (<http://www.terveys2000.fi/indexe.html>).

Assessment of HRQoL
-------------------

The HRQoL was assessed using the self-administered Airways Questionnaire 20 \[[@B27]\] and 15D (<http://www.15d-instrument.net/15D>). All participants filled in both questionnaires during the research visit without any guidance from the research personnel. The AQ20 questionnaire was used as the disease-specific instrument of HRQoL. This questionnaire was developed in 1998 for use in asthma \[[@B27]\] and COPD \[[@B22],[@B28]\]. The AQ20 is a uni-dimensional measure containing 20 items with "yes" responses are scored as 1, and "no" and "not applicable" are scored as 0. The scores of 1 are summed up to obtain the AQ20 summary score, which ranges from 0 to 20, a score of zero indicating no respiratory symptoms or worries about the disease. The 15D--instrument \[[@B29]\] is a generic, multidimensional, standardized, self-administered evaluative tool of HRQoL that can be used primarily as a single index measure, but also as a profile measure. It describes the health status, with 15 dimensions, namely: mobility, vision, hearing, breathing, sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, depression, distress, vitality, and sexual activity. Each dimension comprises one question on a 5-point scale. A single index score is obtained by incorporating population-based preference weights to the 15 dimensions. The maximum score is 1 (no problems on any dimension) and the minimum score is 0 (being dead). The 15D instrument has good test--retest reliability, construct validity, and discriminatory power in general populations \[[@B23]\] and has been validated for use in COPD \[[@B30],[@B31]\]. All participants returned the questionnaire at the recruitment session. There was no missing data for AQ20, for 15D eight patients did not finish the questionnaire completely and this data was omitted from analysis. Recall bias was not assessed in this study.

Physiological measurements and co-morbid conditions
---------------------------------------------------

All hospitals, health care centres, and other outpatient clinics that had treated the patients were contacted to archive a complete medical history for each participant. The patients' social security number was used to combine the data from different sources. Source data with personal identifiers were managed and stored in the Clinical Research Centres administered by the Helsinki and Turku University Central Hospitals. The results of flow-volume spirometry including bronchodilatation tests nearest to index date, diffusion capacity, ECGs at rest, weight, height and smoking status were used in the analysis. The reference values used for FEV~1~ and FVC in Finnish clinical practice were validated in large Finnish population samples consisting of both genders and a wide range of age groups \[[@B32]\]. All the given diagnoses stated in the medical records were carefully evaluated; especially concerning the time of onset and certainty of the diagnosis was determined. Category 'coronary disease' included the patients who have had a myocardial infarction, acute coronary artery syndrome, or angina pectoris diagnosed by an internist or cardiologist. 'Cerebrovascular diseases' included patients with strokes and transient ischemic attacks diagnosed by a neurologist. 'Cardiovascular diseases' consisted of patients having one of the following diseases: coronary, cerebrovascular disease, or peripheral artery occlusive disease. Chronic atrial fibrillation was confirmed by ECG recordings. Category 'diabetes' includes patients with the type 1 and 2 disease. Chronic alcoholism, alcohol use disorder, and treatment of alcohol-use related disorders were categorized as 'alcohol abuse'. A wide range of psychotic disorders and long lasting clinical depression, and anxiety that needed regular medication were categorized as 'Psychiatric condition'. Category 'cancer' included all malignant solid tumours and malignant haematological diseases. The prevalence of the common co-existing diseases were compared with an age and gender matched control population from a Finnish population survey (Health 2000, N = 5000) \[[@B33]\]. Diffusing capacity and ECG were available from a limited number of the patients and therefore excluded from the multivariate regression analyses (Table [1](#T1){ref-type="table"} and Additional file [1](#S1){ref-type="supplementary-material"}: Table S3). The modified Medical Research Council (mMRC) dyspnoea scale was used to measure subjective breathlessness \[[@B34]\].

###### 

Risk factors for low HRQoL (AQ20 summary score ≥14) based on univariate and backwards-stepwise multivariate regression analysis

  **Patient characteristics**      **N of patients analyzed**   **% patients with poor HRQoL**   **Crude OR**   **95%*CI***     **P-value**   **Adjusted OR**   **95%*CI***      **P-value**
  -------------------------------- ---------------------------- -------------------------------- -------------- --------------- ------------- ----------------- ---------------- -------------
  Gender                                                                                                                                                                          
    Male                           422                          10.8                             1.00                                                                             
    Female                         225                          15.4                             1.51           0.97-2.35       NS            **2.11**          **1.27-3.51**    **0.004**
  Age at recruitment                                                                                                                                                              
    \<60 years                     215                          13.5                             1.00                                                                             
    61--68 years                   274                          14.2                             1.06           0.64-1.79       NS                                                
    \>69 years                     250                          9.6                              0.68           0.38-1.21       NS                                                
  FEV~1~ baseline % of predicted                                                                                                                                                  
    \>80                           *95*                         9.5                              1.00                                                                             
    65--80                         *185*                        4.9                              0.50           0.17-1.43       NS            0.54              0.18-1.63        0.27
    40--64                         *323*                        13.3                             1.47           0.63-3.43       NS            **2.48**          **0.99-5.95**    **0.05**
    \<40                           *136*                        22.9                             **2.84**       **1.19-6.79**   **0.02**      **5.17**          **2.03-13.17**   **0.001**
  Smoking cessation succeed                                                                                                                                                       
    Yes                            358                          11.2                             1.00                                                                             
    No                             281                          14.2                             1.32           0.83-2.11       NS                                                
  BMI units                                                                                                                                                                       
    \<19                           33                           34.3                             \-             \-              \-                                                
    19--25                         251                          4.5                              1.00                                                                             
    \>25-30                        275                          37.6                             0.64           0.37-1.07       NS                                                
    \>30                           173                          23.6                             0.95           0.54-1.64       NS                                                
  Diabetes                                                                                                                                                                        
    No                             628                          11.9                             1.00                                                                             
    Yes                            111                          15.3                             1.33           0.75-2.36       NS                                                
  Cardiovascular Disease^1^                                                                                                                                                       
    No                             532                          13.3                             1.00                                                                             
    Yes                            207                          10.1                             0.73           0.44-1.23       NS                                                
  Hypertension                                                                                                                                                                    
    No                             439                          12.3                             1.00                                                                             
    Yes                            300                          12.7                             1.03           0.66-1.61       NS                                                
  Atrial Fibrillation                                                                                                                         \-^2^                               
    No                             474                          14.1                             1.00                                                                             
    Yes                            31                           29.0                             **2.49**       **1.10-5.63**   **0.03**                                          
  Diffusing capacity                                                                                                                                                              
    Normal                         221                          11.8                             1.00                                                                             
    Mild/moderately decrease       89                           11.2                             0.95           0.44-2.06       NS                                                
    Severe decrease                103                          16.5                             1.48           0.77-2.87       NS                                                
  Cancer                                                                                                                                                                          
    No                             695                          12.4                             1.00                                                                             
    Yes                            44                           13.6                             1.12           0.46-2.72       NS                                                
  Psychiatric conditions                                                                                                                                                          
    No                             493                          9.9                              1.00                                                                             
    Yes                            240                          17.1                             **1.87**       **1.19-2.92**   **0.006**     **1.99**          **1.21-3.29**    **0.007**
  Alcohol abuse                                                                                                                                                                   
    No                             629                          10.5                             1.00                                                                             
    Yes                            110                          23.6                             **2.64**       **1.59-4.39**   **\<0.001**   **3.02**          **1.65-5.51**    **0.001**

Odd Ratios with P values ≤0.05 are shown in bold.

^1^coronary, cerebrovascular, or peripheral artery disease, ^2^due to small number of tested patients not included to the multivariate analysis.

The Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District approved the study approach, and the permission to conduct this research was granted by the Helsinki and Turku University Hospitals. All the clinical studies, sample collection and storage, and data gathering processes were done according to the standardised operational procedures (SOPs), the training of the study personnel has been documented and done according to good clinical practice. Clinical study processes have been monitored after enrolment and after each annual follow-up contact with the study subject.

Statistical analysis
--------------------

Analyses were performed by the statistical software packages SPSS (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp) and R Statistical Software (R Development Core Team (2008), R version 2.15, <http://www.R-project.org>).

Correlations of 15D and AQ20 scores with lung function measurements were analysed using the Spearman correlation coefficient. Both HRQoL scores were analysed as continuous and as categorised variables. Analysis of continuous endpoints enables inferences throughout the scale of HRQoL, while categorised endpoints only compare differences between two groups. Thus parallel analysis of categorised and continuous endpoints was used as supportive approach to confirm congruent results. Linear regression was used to determine clinically valid attributes potentially affecting HRQoL and to compare their relative importance. Regression coefficient B is the change in HRQoL when dependent variable changes with one unit. To quantify the effect of a particular dependent variable we determined standardized regression coefficient β, which is a modification of B. The effect is standardized from -1 to 1 allowing solid comparison between the variables. Differences in means of FEV~1~ % of predicted were determined using ANOVA combined with Tukey\'s Honestly Significant Difference.

The 10.0% (in 15D) and 12.4% (closest discrete value to 10% in AQ20) of patients having the lowest HRQoL score formed the low-HRQoL subgroup. Logistic backwards-stepwise regression was used to determine the independent risk factors for low HRQoL. All covariates presented as crude ORs (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}) were included into backwards-stepwise logistic regression to construct a multivariate model defining independent risk factors for poor HRQoL. The model constructed for poor 15D was then used to assess its performance in predicting 5-year mortality by determining Receiver Operating Characteristic (ROC) and Area Under the Curve (AUC). The Minimal Clinically Important Difference (MCID) in 15D total score is 0.03 \[[@B35]\]. Analyses were done separately for both 15D (Table [2](#T2){ref-type="table"}) and AQ20 (Table [1](#T1){ref-type="table"}).

###### 

Risk factors for a low score on 15D (total score ≤0.65) based on univariate and backwards stepwise multivariate regression analysis

  **Patient characteristics**      **N of patients analyzed**   **% patients with poor HRQoL**   **Crude OR**   **95%*CI***     **P-value**   **Adjusted OR**   **95%*CI***     **P-value**
  -------------------------------- ---------------------------- -------------------------------- -------------- --------------- ------------- ----------------- --------------- -------------
  Gender                                                                                                                                                                         
    Male                           470                          9.6                              1.00                                                                            
    Female                         261                          11.1                             1.18           0.72-1.93       NS                                               
  Age at recruitment                                                                                                                                                             
    \<60 years                     214                          9.8                              1.00                                                                            
    61--68 years                   269                          10.4                             1.97           0.59-1.94       NS                                               
    \>69 years                     248                          10.1                             1.03           0.56-1.90       NS                                               
  FEV~1~ baseline % of predicted                                                                                                                                                 
    \>80                           *94*                         8.2                              1.00                                         1.00                               
    65--80                         *184*                        7.5                              0.91           0.33-1.39       NS            1.02              0.35-3.01       NS
    40--64                         *318*                        9.8                              1.21           0.53-1.88       NS            1.41              0.52-3.80       NS
    \<40                           *135*                        16.5                             2.21           0.86-5.71       0.100         **3.08**          **1.10-8.63**   **0.03**
  Smoking cessation succeed                                                                                                                                                      
    Yes                            355                          7.9                              1.00                                                                            
    No                             278                          12.6                             **1.68**       **1.00-2.84**   **0.05**                                         
  BMI units                                                                                                                                                                      
    \<19                           32                           9.3                              0.65           0.15-2.91       NS                                               
    19--25                         248                          6.2                              1.00                                                                            
    \>25-30                        272                          9.2                              0.99           0.55-1.79       NS                                               
    \>30                           172                          14.0                             1.59           0.86-2.92       NS                                               
  Diabetes                                                                                                                                                                       
    No                             620                          8.4                              1.00                                         1.00                               
    Yes                            111                          19.8                             **2.70**       **1.56-4.66**   **\<0.001**   **2.12**          **1.07-4.22**   **0.03**
  Cardiovascular Disease^1^                                                                                                                                                      
    No                             526                          9.1                              1.00                                         1.00                               
    Yes                            205                          12.7                             1.45           0.87-2.40       NS            1.69              0.93-3.07       0.09
  Hypertension                                                                                                                                                                   
    No                             434                          9.4                              1.00                                                                            
    Yes                            297                          11.1                             1.20           0.74-1.94       NS                                               
  Atrial Fibrillation                                                                                                                                                            
    No                             468                          11.1                             1.00                                         \-^2^                              
    Yes                            30                           23.3                             **2.44**       **1.00-5.95**   **0.05**                                         
  Diffusing capacity                                                                                                                                                             
    Normal                         220                          10.0                             1.00                                                                            
    Mild/Moderately decrease       87                           13.8                             1.44           0.68-3.05       NS                                               
    Severe decrease                102                          11.8                             1.20           0.57-2.53       NS                                               
  Cancer                                                                                                                                                                         
    No                             687                          10.0                             1.00                                                                            
    Yes                            44                           11.4                             1.15           0.44-3.01       NS                                               
  Psychiatric conditions                                                                                                                                                         
    No                             488                          5.9                              1.00                                         1.00                               
    Yes                            237                          18.1                             **3.51**       **2.13-5.78**   **\<0.001**   **4.65**          **2.57-8.40**   **\<0.001**
  Alcohol abuse                                                                                                                                                                  
    No                             621                          8.4                              1.00                                         1.00                               
    Yes                            110                          20.0                             **2.74**       **1.58-4.73**   **\<0.001**   **2.33**          **1.21-4.49**   **0.007**

Odd Ratios with P values ≤0.05 are shown in bold.

^1^coronary, cerebrovascular, or peripheral artery disease, ^2^due to small number of tested patients not included to the multivariate analysis.

Results
=======

Study subjects
--------------

A total of 739 eligible patients (64% male, mean age 64 ± SD 7 years, mean pack years 51 **±** SD 20) with COPD attended the study. The patients were identified through a two-phase mailing campaign, which was directed to all elderly asthma, and COPD patients who had visited the University Hospital of Helsinki and Turku years 1995--2006 \[[@B26]\]. The diagnosis was made on average 5.5 years before the enrolment. The severity of the disease was determined by the latest flow volume spirometry, which was performed within two years before the recruitment. According to the GOLD criteria \[[@B36]\], the majority of the patients belonged to the stages 2--3, moderate to severe COPD.

Even though women had slightly better lung function (mean FEV~1~ 55 vs. 61% of predicted, p \< 0.001), they reported higher scores for several questions related to respiratory symptoms and the mean AQ20 summary score was significantly higher among women than men (7.9 vs. 8.8 p = 0.02) (Additional file [1](#S1){ref-type="supplementary-material"}: Table S2). For 15D the total score did not differ (0.79 for both sexes). Women, however, reported more difficulties with sleep, depression, and distress than men. Men suffered more frequently from impairment of sexual performance than women (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1).

Co-morbidities in the cohort
----------------------------

Common co-morbidities of the COPD patients were evaluated from the medical records (Table [3](#T3){ref-type="table"}). Cardiovascular diseases, diabetes, and chronic psychiatric conditions were more prevalent in the COPD cohort than among the gender and age matched Finnish controls.

###### 

Prevalence of co-morbidities in the COPD cohort compared to those in an age and gender matched Finnish population survey

  **Chronic disease**              **COPD cohort N = 739**   **Finnish population cohorts health 2000N = 5000**               
  -------------------------------- ------------------------- ---------------------------------------------------- ---- ------ -------
  Hypertension                     41                        40                                                   41   \-      
  Coronary disease                 27                        12                                                   22   16     1.4 x
  Cerebrovascular disease          9                         5                                                    8    5^1^   1.6 x
  Peripheral artery disease        6                         2                                                    5    2      2.5 x
  Diabetes                         18                        11                                                   15   9      1.7 x
  Alcohol abuse                    18                        9                                                    15   \-      
  Chronic psychiatric conditions   26                        45                                                   33   12     2.8 x
  Cancer                           6                         6                                                    6    7      0.9 x

^1^stroke including also intracerebral and subarachnoidal hemorrhage.

The prevalence of co-occurrence of the chronic medical conditions was comparable in males and females, no co-morbidities 27.9% vs. 26.3%, 1 co-morbidity 31.5 vs. 31.9%, 2 co-morbidities 21.4% vs. 26.3%, 3 co-morbidities 14.6% vs. 11.7% and ≥4 co-morbidities 4.7% vs. 3.8% respectively. The number of chronic conditions did not significantly associate with FEV~1~ levels.

Lung function and co-morbidities in relation to HRQoL scores
------------------------------------------------------------

Both FEV~1~ and diffusing capacity correlated with the HRQoL scores weakly or moderately, FEV~1~ slightly stronger than diffusing capacity and both lung function measurement slightly stronger to AQ20 than 15D (Table [4](#T4){ref-type="table"}). The strongest correlation was found between the two HRQoL instruments (r = -0.69). The lung function measures (FEV~1~ and DLCOcVA) were also moderately correlated with each other (r = 0.35).

###### 

Correlation matrix for lung function parameters, HRQoL, MRC Dyspnoea scale and age

                      **15D score**   **Age**       **DLCOcVA**   **FEV1%**     **MRC scale**   **FEV1\*DLCOcVA**   **AQ20 score**
  ------------------- --------------- ------------- ------------- ------------- --------------- ------------------- ----------------
  **15D Score**       1               0.01          0.11\*        0.16\*\*\*    -0.03           0.15\*\*            -0.69\*\*\*
  **Age**             0.01            1             -0.07         -0.19\*\*\*   0.02            -0.17\*\*           -0.09
  **DLCOcVA**         0.11\*          -0.07         1             0.35\*\*\*    0.03            0.79\*\*\*          -0.19\*\*\*
  **FEV1%**           0.16\*\*        -0.19\*\*\*   0.35\*\*\*    1             0.00            0.83\*\*\*          -0.24\*\*\*
  **MRC Scale**       -0.03           0.02          0.03          0.00          1               0.01                0.07
  **FEV1\*DLCOcVA**   0.15\*\*        -0.17\*\*     0.79\*\*\*    0.83\*\*\*    0.01            1                   -0.25\*\*\*
  **AQ20 Score**      -0.69\*\*\*     -0.09         -0.19\*\*\*   -0.24\*\*\*   0.07            -0.25\*\*\*         1

\*p-value \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.

Only a very small proportion of variance (adjusted R^2^ 3.5%) found in the 15D total score was explained by FEV~1~ and diffusion capacity alone. When co-morbidities were added into the model, psychiatric conditions, FEV~1~, alcohol abuse, diabetes, cardiovascular diseases, and hypertension were significant determinants of the total 15D scores. Psychiatric conditions (p ≤ 0.001) and FEV~1~ (p ≤ 0.001) had the greatest effect (β \> 0.2). Alcohol abuse (p ≤ 0.001), cardiovascular diseases (p = 0.006), and diabetes (p = 0.007) had β-values in the range of 0.1 -- 0.2 while hypertension (p = 0.04) had the smallest β (0.08). After performing stepwise regression, explained variance in 15D was increased considerably from 3.5% to 17.6%.

Correspondingly for AQ20, the greatest effect was found for FEV~1~ (β = 0.34, p \< 0.001), while psychiatric conditions (p ≤ 0.001), female gender (p ≤ 0.001), alcohol abuse (p = 0.002) all had β-values in the range of 0.1 -- 0.2, and hypertension had the smallest effect (β \<0.1, p = 0.008). The model including the comorbidities explained 15.5% of the AQ20 summary score, while FEV~1~ and diffusion capacity alone explained only 6.9% of the variation.

Clinical variables explaining low HRQoL
---------------------------------------

The mean 15D total score in the cohort was 0.79 (SD 0.11). Patients with the lowest 10% of the 15D score (N = 79/731, 9.6% of men and 11.1% of women) formed the low 15D category (total score ≤0.65, Table [2](#T2){ref-type="table"}). Diabetes (OR 2.1, 95% CI 1.1-4.2, p = 0.03), psychiatric conditions and alcohol abuse (OR 2.3, 95% CI 1.2-4.5, p = 0.007), were independently associated with a low 15D score. The greatest risk of a low 15D score (OR 4.7, 95% CI 2.6-8.4, p ≤ 0.001) was shown among COPD patients with psychiatric conditions. A low 15D score was significantly related to airway obstruction only when the patients' FEV~1~ was \<40% of predicted. The OR of low 15D score was then three-fold compared to patients with FEV~1~ \> 80% (95% CI 1.1-8.6, p = 0.03).

The mean AQ20 summary score in the cohort was 8.25 (SD = 5.03). The lowest 12.4% of AQ20 (summary score \>14, N = 92/739, 12.1% of men and 18.2% of women) was associated with borderline significance to moderate airway obstruction (OR 2.5, 95% CI 1.0-6.0, p = 0.05, when FEV~1~ 64-40% of predicted) and significantly to severe airway obstruction (OR 5.2, 95% CI 2.0-13.2, p ≤ 0.001, when FEV~1~ \< 40%). Alcohol abuse (OR 3.0, 95% CI 1.7-5.5, p ≤ 0.001) and psychiatric conditions (OR 2.0, 95% CI 1.2-3.3, p = 0.007) were the significant co-morbidities associated with poor AQ20 alongside with female gender (OR 2.1, 95% CI 1.3-3.5, p = 0.004). Contrary to 15D, cardiovascular diseases and diabetes remained non-significant predictors for poor AQ20 score (Table [1](#T1){ref-type="table"}). Thirty-three patients were categorised having low HRQoL by both questionnaires.

The mMRC dyspnoea scale did not remain significant in any of the models after stepwise model selection.

Mortality and HRQoL
-------------------

In order to study the importance of the identified risk factors of low generic HRQoL, the same variables were used in a 5-year mortality model (N~total~ = 670, N~dead~ = 105) (Additional file [1](#S1){ref-type="supplementary-material"}: Table S3). FEV~1~ \< 40% of predicted was the most important risk factor (OR 6.91, 95% CI 2.31 - 20.6, p ≤ 0.001) for mortality. Alcohol abuse (OR 2.15, 95% CI 1.19 - 3.88, p = 0.01) and cardiovascular diseases (OR 1.71, 95% CI 1.06 - 2.73, p = 0.03) were also significant risk predictors, while diabetes and psychiatric conditions remained non-significant. The model showed a substantial prognostic value of mortality (AUC = 0.70). Both HRQoL scores were compromised among the patients who died compared to those who lived throughout the follow-up period (for 15D score 0.75 vs. 0.80, p ≤ 0.001 and for AQ20 score 9.82 vs. 7.99, p ≤ 0.001).

Discussion
==========

The present patient cohort was hospital based representing all severity stages of the disease \[[@B26]\]. To analyse patients' airway specific and generic HRQol we used two questionnaires. Both questionnaires are validated, well correlated and short enough to be integrated in clinical practise \[[@B25]\]. Our results show that cardiovascular diseases, diabetes, alcohol abuse, and different psychiatric diseases were more frequent in COPD patients than in controls. Like in previous reports, neither a particular co-morbidity nor the total number of co-morbidities correlated to the severity of airway obstruction \[[@B37]\]. However, co-morbidities were the most important determinants of HRQoL in subjects with mild and moderate severe obstruction. Only the presence of severe obstruction (FEV~1~ \< 40%) was a significant contributor of HRQoL. Using the multivariate regression models, we found that co-morbidities were associated both with general and respiratory specific HRQoL, the strongest effects being observed for psychiatric conditions that needed regular medications and alcohol abuse. The co-morbidities were diagnosed typically years before the HRQoL-measure at study baseline, and thus could be considered as risk factors of poor HRQoL. Although this suggests causality, it cannot be confirmed in this cross-sectional study. The present study cohort reflects the heterogeneity found in COPD at large. The patients represented both genders and all severity stages of airway obstruction, and various patterns of co-morbidities were present, including cardiovascular diseases, chronic atrial fibrillation, hypertension, diabetes, obesity, psychiatric conditions, cancer, and alcohol abuse, confirming previous reports on multimorbidity in COPD \[[@B4],[@B38]\].

Accumulation of comorbidities into the present COPD cohort was less than in some previous reports. In the present data set the diagnoses are based on retrospective medical records, but COPD patients may go under diagnosed when the symptoms of co-existing disease are not recognised or the symptoms are considered adverse events of COPD medication. Underestimation of co-existing diseases would thus weaken the role of co-morbidities explaining the variability found in HRQoL. Two to three times higher risk of cardiovascular diseases has been reported in several COPD populations \[[@B38],[@B39]\]. Incompatibilities in the diagnostic criteria and differences in characteristics of COPD populations may explain to some extent the inconsistencies between studies. Preventive care for example in coronary disease has become more active over time which might explain why COPD patients were at significant risk of lung cancer, heart failure, and death, but not at risk of myocardial infarction \[[@B40]\]. In the present COPD cohort the diagnoses were given by a specialist and gathered from medical records. The diagnoses can be considered more plausible than self-reported often used in previous reports. The prevalence may also reflect recruitment bias, i.e. if the most seriously ill patients did not participate. Excessive alcohol consumption was pronounced among COPD patients. Compared to elderly Finns in general, alcohol abuse was 4.5 fold more frequent among women and 2.3 fold more frequent among men with COPD \[[@B41]\]. Excess alcohol use has been found also in other COPD populations \[[@B42]\]. Data on chronic atrial fibrillation and diffusing capacity were not available for all, but the univariate model suggested that chronic atrial fibrillation would harm HRQoL (crude OR 2.4, 95% CI 1.00-6.0, p ≤ 0.05), while impaired diffusing capacity did not. Prevalence of hypertension (41%) and chronic atrial fibrillation (6%) were at the same level as in general age and gender matched population in Finland \[[@B43]\].

Like in many previous studies, lung function alone was not a strong predictor of either respiratory or general HRQoL \[[@B22],[@B44],[@B45]\]. Literature on co-morbidities as determinants of HRQoL in COPD is rather sparse. Using St George's Respiratory Questionnaire (SGRQ) in primary health care COPD population (N = 1817) it has been shown that patient with \>3 co-morbidities had poorer HRQoL than patients with 1--2 comorbidities \[[@B46]\]. In patients with \<3 co-morbidities the generic instrument was more sensitive than SGRQ suggesting that respiratory specific HRQoL is not influenced by the presence of low levels of co-morbidity. In another study (N = 326 COPD patients) the presence of dyspnoea and exacerbation, depression was the most important contributor to HRQoL impairment measured by SGRQ, whereas other comorbidities had only limited impact \[[@B47]\]. When 23 co-morbid diseases were analysed in a COPD cohort (N = 659, matching age and slightly more advanced disease than in the present study), the presence of three or more co-morbid diseases was more predictive of HRQoL than any demographic variable or physiological measurement \[[@B45]\]. Insomnia, however, was the only separate disease that correlated to general HRQoL. In another study by Putcha et al. (N = 843), four out of thirteen comorbid diseases (congestive heart failure, arthritis, diabetes, incontinence/prostate disease) associated independently with generic HRQoL \[[@B37]\]. All diagnostic information was based on self-reported data and the severity of COPD was not known in the latter study. These study designs included depression, but no other psychiatric or any addictive diseases like in our study. COPD patients in the present study displayed a large scale of psychiatric symptoms from features of psychosis to rather mild anxiety or depression. Not all of them had received a thorough psychiatric evaluation and thus the exact nature of the disease remained unknown, but the common nominator was the use of regular psychiatric medication. Psychiatric conditions (OR for low HRQoL for 15D 4.7 and for AQ20 2.0) and alcohol abuse (OR for 15D 2.3 and for AQ20 3.0) both had a strong impact on HRQoL that could be detected by generic and respiratory specific instruments. Our data also showed that diabetes affected generic HRQoL (OR 2.1) while cardiovascular diseases showed a similar trend even though not significant (OR 1.7). FEV~1~ was also a strong predictor of both generic and respiratory specific HRQoL, however the effect was significant only at late stages of disease (FEV~1~ \< 40% of predicted).

Comparably with findings in the general population, cardiovascular morbidity was more prevalent among men than among women. Women reported significantly more respiratory symptoms even though their FEV~1~ was slightly better, as also reported earlier \[[@B48]\]. Regarding functional inabilities, women more often had sleeping difficulties, depression and distress while men suffered more often from impaired sexual performance.

At present, there is some evidence that HRQoL has predictive value for risk of exacerbations, use of health care resources, and mortality in COPD \[[@B49],[@B50]\]. In the present study generic HRQoL was statistically (p ≤ 0.001) and clinically (MCID \>0.03) poorer among patients who died within the next five years. If the patients' 15D score was \<0.815 his risk to die during the next five years was 2.3 times higher than among the rest of the patients (p ≤ 0.001). Correspondingly for AQ20 score \>7.5 was associated with high mortality rate (OR = 2.16, p ≤ 0.001). The clinical variables, which predicted both poor HRQoL and mortality, were FEV~1~, alcohol abuse, and cardiovascular diseases. HRQoL has been considered a potential component to the new multidimensional health status --measures in COPD \[[@B12]\]. Our results also suggest that HRQoL might provide a broader insight in predicting mortality than FEV~1~ alone.

Recent studies have shown clearly that COPD can no longer be assessed as a disease only involving the lungs \[[@B51]\]. Even though COPD has pulmonary and extra-pulmonary manifestations both the generic and respiratory specific instruments gave surprisingly consistent results. The most important risk factors for poor HRQoL were identified by both instruments and by both analysis approaches applied. The risk factors for increased mortality were also partially overlapping and the HRQoL score was *per se* correlated with mortality. We have previously shown that when multiple HRQoL measures over five years are available for asthma and COPD patients constantly declining trends can be recognized with high probability \[[@B52]\]. In clinical practice the great benefit of the generic HRQoL instrument is that it allows the comparison of treatment interventions not only among COPD patients, but also in comparison to other patient groups suffering chronic diseases. Effectiveness of treatment options can be compared by using the 'quality adjusted life years' (QALY) measurement. Further this measurement allows us to consider the cost effectiveness of the treatment e.g. how much the treatments option costs per achieved QALY. It is an important additional feature in HRQoL studies, since disease burden of COPD is significant for public health care.

Conclusion
==========

Our results suggest that the effect of co-morbidities in COPD is underestimated in regard of HRQoL. Psychiatric conditions, alcohol abuse, cardiovascular disease and lung function are comparably important in predicting the HRQoL of a COPD patient. These findings are further underlined by the higher prevalence of these conditions in this hospital based COPD cohort, when compared to age and gender matched general population. We chose for the study two short and easy to fill-in questionnaires and thus applicable also in clinical practice. The instruments have been validated in COPD and they have been shown to correlate to other more complex questionnaires. Being generic, 15D better captured the impact of co-morbidities while respiratory specific AQ20 was more sensitive to impaired lung function. Five-year mortality was significantly higher in patients with poor HRQoL measure at study baseline.
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